Disease · MONDO_0008487

polycystic ovary syndrome

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. polycystic ovary syndrome. Diseases, record MONDO_0008487. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0008487

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: polycystic ovary syndrome; Open Targets
Open Targets ID: MONDO_0008487; Open Targets
Other names: Cystic disease of ovaries, Multicystic ovaries, Ovarian Degeneration, Sclerocystic, Ovarian Syndrome, Polycystic, Ovarian Syndromes, Polycystic, Ovaries, Sclerocystic, Ovary Syndrome, Polycystic, Ovary, Sclerocystic, PCO - Polycystic ovaries, PCOD - Polycystic ovarian disease, PCOS, PCOS - Polycystic ovarian syndrome, Polycystic ovarian syndrome, Polycystic ovaries (disorder), Sclerocystic Ovarian Degeneration, Sclerocystic Ovaries, Sclerocystic Ovary, Sclerocystic Ovary Syndrome, Stein Leventhal Syndrome, Stein-Leventhal synd., Syndrome, Polycystic Ovary, Syndrome, Stein-Leventhal, polycystic ovarian disease, polycystic ovaries, polycystic ovary; Open Targets
Disease Ontology: DOID:11612; Disease Ontology
MeSH: D011085; MeSH
NCI Thesaurus: C26862; NCI Thesaurus
Orphanet: ORPHA:3185; Orphanet
Highest stage of its drugs: Approval, for 2 of its 118 drugs, from DailyMed and TTD; Open Targets

Drugs118

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CLOMIPHENE CITRATE	CHEMBL3185958	Small molecule	Approval	DailyMed	50	49	49	Drugs and targets
HISTRELIN	CHEMBL1201255	Protein	Approval	TTD	1	0	0	Drugs and targets
METFORMIN	CHEMBL1431	Small molecule	Phase 3	ClinicalTrials.gov	135	135	135	Drugs and targets
LETROZOLE	CHEMBL1444	Small molecule	Phase 3	ClinicalTrials.gov	51	51	51	Drugs and targets
ETHINYL ESTRADIOL	CHEMBL691	Small molecule	Phase 3	ClinicalTrials.gov	28	28	21	Drugs and targets
INOSITOL	CHEMBL1222251	Small molecule	Phase 3	ClinicalTrials.gov	26	26	21	Drugs and targets
DROSPIRENONE	CHEMBL1509	Small molecule	Phase 3	ClinicalTrials.gov	14	14	8	Drugs and targets
FOLLITROPIN	CHEMBL4297955		Phase 3	ClinicalTrials.gov	12	12	11	Drugs and targets
ERGOCALCIFEROL	CHEMBL1536	Small molecule	Phase 3	ClinicalTrials.gov	10	10	10	Drugs and targets
MENOTROPINS	CHEMBL2108427	Protein	Phase 3	ClinicalTrials.gov	10	10	1	Drugs and targets

1 to 10 of 118

See all 118 drugs

Targets164

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PGR	Progesterone receptor	11	Progesterone receptor agonist; Progesterone receptor modulator	Phase 3	https://conductscience.org/library/genes/5241	Drugs and targets
GNRHR	Gonadotropin-releasing hormone receptor	10	Gonadotropin-releasing hormone receptor agonist; Gonadotropin-releasing hormone receptor antagonist	Approval	https://conductscience.org/library/genes/2798	Drugs and targets
ESR1	Estrogen receptor	6	Estrogen receptor alpha agonist; Estrogen receptor alpha modulator; Estrogen receptor modulator	Approval	https://conductscience.org/library/genes/2099	Drugs and targets
FSHR	Follicle-stimulating hormone receptor	6	Follicle stimulating hormone receptor agonist	Phase 3	https://conductscience.org/library/genes/2492	Drugs and targets
NR3C1	Glucocorticoid receptor	6	Glucocorticoid receptor agonist; Glucocorticoid receptor antagonist	Phase 2/3	https://conductscience.org/library/genes/2908	Drugs and targets
AR	Androgen receptor	4	Androgen Receptor agonist; Androgen Receptor antagonist	Phase 2/3	https://conductscience.org/library/genes/367	Drugs and targets
SLC5A2	Sodium/glucose cotransporter 2	4	Sodium/glucose cotransporter 2 inhibitor	Phase 3	https://conductscience.org/library/genes/6524	Drugs and targets
GLP1R	Glucagon-like peptide 1 receptor	3	Glucagon-like peptide 1 receptor agonist	Phase 3	https://conductscience.org/library/genes/2740	Drugs and targets
LHCGR	Lutropin-choriogonadotropic hormone receptor	3	Luteinizing hormone/Choriogonadotropin receptor agonist	Phase 3	https://conductscience.org/library/genes/3973	Drugs and targets
PPARG	Peroxisome proliferator-activated receptor	3	Peroxisome proliferator-activated receptor agonist; Peroxisome proliferator-activated receptor gamma agonist	Phase 2/3	https://conductscience.org/library/genes/5468	Drugs and targets

1 to 10 of 164

See all 164 targets

Trials329

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 8 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00719186	Pregnancy in Polycystic Ovary Syndrome II	Phase 3	750	2014-06-09	Pregnancy, Polycystic Ovary Syndrome	CLOMIPHENE CITRATE, LETROZOLE	Its record names the disease	ClinicalTrials.gov
NCT03229057	Comparing the Effects of Oral Contraceptive Pills Versus Metformin	Phase 3	240	2025-03-10	PCOS	DESOGESTREL, ETHINYL ESTRADIOL, METFORMIN	Its record names the disease	ClinicalTrials.gov
NCT00704912	Treatment of Hyperandrogenism Versus Insulin Resistance in Infertile Polycystic Ovary Syndrome (PCOS) Women	Phase 2	217	2015-12-17	Polycystic Ovary Syndrome	ORLISTAT	Its record names the disease	ClinicalTrials.gov
NCT01622257	Cavitation Ultrasound in Treatment of Patients With PCOS	Phase 2	198	2013-02-07	PCOS	METFORMIN	Its record names the disease	ClinicalTrials.gov
NCT01185704	Analysis of Two Therapeutic With Cetrotide® in Polycystic Ovarian (PCO) Women in Assisted Reproductive Technology (ART)	Phase 3	136	2013-07-03	Polycystic Ovarian Syndrome	CETRORELIX ACETATE	Its record names the disease	ClinicalTrials.gov
NCT02635386	EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)	Phase 3	119	2021-01-29	Polycystic Ovary Syndrome, Obesity	DAPAGLIFLOZIN, EXENATIDE, METFORMIN, PHENTERMINE, TOPIRAMATE	Its record names the disease	ClinicalTrials.gov
NCT03951077	Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome	Phase 2	118	2022-06-08	Polycystic Ovary Syndrome	ELAGOLIX	Its record names the disease	ClinicalTrials.gov
NCT00151411	Lifestyle Intervention and Metformin for Women With Polycystic Ovary Syndrome (PCOS)	Phase 2	114	2011-11-08	Polycystic Ovary Syndrome	METFORMIN	Its record names the disease	ClinicalTrials.gov
NCT03117517	Treatment With Metformin and Combination of Metformin and Pioglitazone in Polycystic Ovarian Syndrome	Early phase 1	106	2020-03-02	Polycystic Ovarian Syndrome	METFORMIN, PIOGLITAZONE	Its record names the disease	ClinicalTrials.gov
NCT01909141	Ovulation Induction in Women With Clomiphene Citrate Resistant PCOS	Early phase 1	100	2015-03-02	Polycystic Ovary Syndrome, Infertility	LETROZOLE, METFORMIN, PIOGLITAZONE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 329

See all 329 trials

Comparisons in its trials45

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Arm A: Clomiphene Citrate vs Arm B: Letrozole: Live Birth	72 of 376	103 of 374	750	NCT00719186	Trial comparisons
Arm A: Clomiphene Citrate vs Arm B: Letrozole: Number of Pregnancy	103 of 376	154 of 374	750	NCT00719186	Trial comparisons
Arm A: Clomiphene Citrate vs Arm B: Letrozole: serious adverse events	13 of 376	21 of 374	750	NCT00719186	Trial comparisons
Day 1 Protocol vs Day 7 Protocol: serious adverse events	2 of 65	4 of 65	130	NCT01185704	Trial comparisons
Metformin vs Placebo: serious adverse events	0 of 55	0 of 59	114	NCT00151411	Trial comparisons
Arm 1:Letrozole-pioglitazone -Metformin Group vs Arm 2: Clomiphene Citrate-pioglitazone-metformin: Pregnancy Rate	28 of 50	24 of 50	100	NCT01909141	Trial comparisons
Arm 1:Letrozole-pioglitazone -Metformin Group vs Arm 2: Clomiphene Citrate-pioglitazone-metformin: serious adverse events	0 of 50	0 of 50	100	NCT01909141	Trial comparisons
Clomiphene Citrate vs Raloxifene: serious adverse events	0 of 40	0 of 42	82	NCT00427700	Trial comparisons
Liraglutide Pen Injector (Saxenda) vs Placebo Liraglutide Pen Injector: deaths from any cause	0 of 55	0 of 27	82	NCT03480022	Trial comparisons
Liraglutide Pen Injector (Saxenda) vs Placebo Liraglutide Pen Injector: serious adverse events	0 of 55	0 of 27	82	NCT03480022	Trial comparisons

1 to 10 of 45

See all 45 comparisons in its trials

Papers from its trials248

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
37098539	RESULT	1	PubMed
35774693	RESULT	1	PubMed
34583840	RESULT	1	PubMed
34220713	RESULT	1	PubMed
33552465	RESULT	1	PubMed
32442310	RESULT	1	PubMed
31867117	RESULT	1	PubMed
31733195	RESULT	1	PubMed
31523136	RESULT	1	PubMed
31238940	RESULT	1	PubMed

1 to 10 of 248

See all 248 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0008487

GET https://conductscience.org/api/diseases/v1/MONDO_0008487/drugs?page=2

API reference For AI assistants